DSpace Repository

RNAi-based therapeutics and tumor targeted delivery in cancer

Show simple item record

dc.contributor.author Kara, Goknur
dc.contributor.author Calin, George A.
dc.contributor.author Ozpolat, Bulent
dc.date.accessioned 2024-03-15T11:51:54Z
dc.date.available 2024-03-15T11:51:54Z
dc.date.issued 2022
dc.identifier.citation Kara, G., Calin, GA., Ozpolat, B. (2022). RNAi-based therapeutics and tumor targeted delivery in cancer. Adv. Drug Deliv. Rev., 182. https://doi.org/10.1016/j.addr.2022.114113 en_US
dc.identifier.issn 0169-409X
dc.identifier.issn 1872-8294
dc.identifier.uri http://dx.doi.org/10.1016/j.addr.2022.114113
dc.identifier.uri https://www.webofscience.com/wos/woscc/full-record/WOS:001026669000001
dc.identifier.uri http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/4563
dc.description WoS Categories: Pharmacology & Pharmacy en_US
dc.description Web of Science Index: Science Citation Index Expanded (SCI-EXPANDED) en_US
dc.description Research Areas: Pharmacology & Pharmacy en_US
dc.description.abstract Over the past decade, non-coding RNA-based therapeutics have proven as a great potential for the development of targeted therapies for cancer and other diseases. The discovery of the critical function of microRNAs (miRNAs) has generated great excitement in developing miRNA-based therapies. The dysregulation of miRNAs contributes to the pathogenesis of various human diseases and cancers by modulating genes that are involved in critical cellular processes, including cell proliferation, differentiation, apoptosis, angiogenesis, metastasis, drug resistance, and tumorigenesis. miRNA (miRNA mimic, anti-miRNA/antagomir) and small interfering RNA (siRNA) can inhibit the expression of any cancer-related genes/mRNAs with high specificity through RNA interference (RNAi), thus representing a remarkable therapeutic tool for targeted therapies and precision medicine. siRNA and miRNA-based therapies have entered clinical trials and recently three novel siRNA-based therapeutics were approved by the Food and Drug Administration (FDA), indicating the beginning of a new era of targeted therapeutics. The successful clinical applications of miRNA and siRNA therapeutics rely on safe and effective nanodelivery strategies for targeting tumor cells or tumor microenvironment. For this purpose, promising nanodelivery/nanoparticle-based approaches have been developed using a variety of molecules for systemic administration and improved tumor targeted delivery with reduced side effects. In this review, we present an overview of RNAi-based therapeutics, the major pharmaceutical challenges, and the perspectives for the development of promising delivery systems for clinical translation. We also highlight the passive and active tumor targeting nanodelivery strategies and primarily focus on the current applications of nanoparticle-based delivery formulations for tumor targeted RNAi molecules and their recent advances in clinical trials in human cancers. Published by Elsevier B.V. en_US
dc.language.iso eng en_US
dc.publisher ELSEVIER-AMSTERDAM en_US
dc.relation.isversionof 10.1016/j.addr.2022.114113 en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject siRNA, miRNA, Non-coding RNAs, Cancer, Nanoparticles en_US
dc.subject CALCIUM-PHOSPHATE NANOPARTICLES, SYSTEMICALLY ADMINISTERED SIRNA, POLYMER-BASED NANOPARTICLE, IN-VITRO EVALUATION, CHITOSAN NANOPARTICLES, ENHANCED PERMEABILITY, INTERFERING RNA, PROMOTES PROLIFERATION, HYALURONIC-ACID, NONVIRAL NANOCARRIERS en_US
dc.title RNAi-based therapeutics and tumor targeted delivery in cancer en_US
dc.type article en_US
dc.relation.journal ADVANCED DRUG DELIVERY REVIEWS en_US
dc.contributor.department Ordu Üniversitesi en_US
dc.contributor.authorID 0000-0001-8602-7463 en_US
dc.identifier.volume 182 en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account